Sight Sciences (NASDAQ:SGHT - Get Free Report) had its price objective reduced by investment analysts at Citigroup from $4.50 to $4.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a "neutral" rating on the stock. Citigroup's target price indicates a potential upside of 16.28% from the company's previous close.
A number of other analysts have also recently commented on SGHT. Lake Street Capital upgraded Sight Sciences from a "hold" rating to a "buy" rating and upped their price objective for the company from $3.00 to $5.00 in a research report on Friday, August 8th. Morgan Stanley boosted their price target on Sight Sciences from $3.00 to $4.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Wall Street Zen raised Sight Sciences from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. Weiss Ratings reissued a "sell (d-)" rating on shares of Sight Sciences in a report on Saturday, September 27th. Finally, Piper Sandler reissued a "neutral" rating and set a $4.00 price target (up previously from $3.50) on shares of Sight Sciences in a report on Wednesday, June 18th. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $4.33.
Check Out Our Latest Stock Analysis on SGHT
Sight Sciences Stock Performance
Sight Sciences stock traded up $0.08 during mid-day trading on Tuesday, reaching $3.44. 110,435 shares of the stock traded hands, compared to its average volume of 184,733. The stock has a market capitalization of $180.15 million, a PE ratio of -3.61 and a beta of 2.41. The company has a debt-to-equity ratio of 0.57, a current ratio of 10.01 and a quick ratio of 9.49. Sight Sciences has a 12-month low of $2.03 and a 12-month high of $6.29. The business's 50-day moving average is $3.74 and its 200-day moving average is $3.48.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. The company had revenue of $19.56 million during the quarter, compared to analysts' expectations of $18.18 million. Sight Sciences had a negative return on equity of 59.38% and a negative net margin of 64.23%. Sight Sciences has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Sight Sciences will post -0.99 EPS for the current fiscal year.
Insider Transactions at Sight Sciences
In other news, insider Jeremy B. Hayden sold 9,731 shares of the company's stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $3.27, for a total value of $31,820.37. Following the completion of the transaction, the insider owned 256,590 shares of the company's stock, valued at $839,049.30. This represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Paul Badawi sold 24,441 shares of the company's stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $3.34, for a total value of $81,632.94. Following the completion of the transaction, the chief executive officer directly owned 5,962,502 shares of the company's stock, valued at approximately $19,914,756.68. This trade represents a 0.41% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,205 shares of company stock valued at $133,181. Corporate insiders own 28.90% of the company's stock.
Hedge Funds Weigh In On Sight Sciences
A number of hedge funds have recently made changes to their positions in the business. CWM LLC boosted its stake in Sight Sciences by 70.2% during the second quarter. CWM LLC now owns 7,607 shares of the company's stock valued at $31,000 after buying an additional 3,137 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Sight Sciences by 32.7% during the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company's stock valued at $48,000 after buying an additional 2,875 shares during the last quarter. Bank of Montreal Can bought a new position in Sight Sciences during the second quarter valued at approximately $49,000. Vanguard Personalized Indexing Management LLC boosted its stake in Sight Sciences by 38.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,888 shares of the company's stock valued at $66,000 after buying an additional 4,453 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Sight Sciences during the second quarter valued at approximately $67,000. Institutional investors own 55.51% of the company's stock.
About Sight Sciences
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sight Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.
While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
